Eli Lilly to construct US$6.5bn Texas pharmaceutical manufacturing site

Render of the future Eli Lilly manufacturing facility in Texas, US. Image: Eli Lilly

The site, Lilly’s eighth US manufacturing facility announced since 2020, will produce small-molecule synthetic medicines, including the company’s pipeline treatments for cardiometabolic health, oncology, immunology, neuroscience and obesity.

Construction will create about 4,000 jobs, with 615 permanent positions to follow in engineering, operations and laboratory work. Lilly said the facility should be operational within five years.

Lilly said the project will incorporate digital automation, advanced analytics and AI systems across its production lines. The company will also work with Texas universities on workforce development and invest in educational initiatives to build local talent pipelines.

The Texas facility is the second of four new US manufacturing sites Lilly has committed to build this year, following a recent announcement in Virginia.